Evaluation of ZAR1 and SFRP4 methylation status as potentials biomarkers for diagnosis in cervical cancer: exploratory study phase I

Biomarkers. 2014 May;19(3):181-8. doi: 10.3109/1354750X.2013.867535.

Abstract

Context: Aberrant hypermethylation of promoter region of tumor suppressor genes could be used as cancer biomarkers.

Objective: To test methylation status of ZAR1 and SFRP4 promoter regions as potentials biomarkers for diagnosis of preneoplastic and neoplastic lesions of cervix.

Materials and methods: Cytobrush samples were evaluated by Methylation specific PCR (MSP) and quantitative MSP (qMSP).

Results: ZAR1 and SFRP4 methylation frequency increased as the grade of lesion increased and the differences between normal and cervical cancer (CC) are statistically significant (p < 0.0001). qMSP showed higher ZAR1 and SFRP4 methylation levels in cancer than normal epithelia (p < 0.001) and preneoplastics lesions (p < 0.01).

Discussion: qMSP quantify methylation levels and have high sensitivity and specificity.

Conclusion: ZAR1 and SFRP4 qMSP could be used as potential biomarker for CC diagnosis.

Publication types

  • Clinical Trial, Phase I
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Base Sequence
  • Biomarkers, Tumor / genetics*
  • DNA Methylation*
  • DNA Primers
  • Egg Proteins / genetics*
  • Female
  • Humans
  • Middle Aged
  • Polymerase Chain Reaction
  • Proto-Oncogene Proteins / genetics*
  • Uterine Cervical Neoplasms / diagnosis*
  • Uterine Cervical Neoplasms / genetics
  • Young Adult

Substances

  • Biomarkers, Tumor
  • DNA Primers
  • Egg Proteins
  • Proto-Oncogene Proteins
  • SFRP4 protein, human
  • Zar1 protein, human